Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 16/20 | 0.62 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.33 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL156369 | 0.90 | MCHR1 (0.66) | MCHR1KCNH2 | |
| SCHEMBL155573 | 0.78 | MCHR1 (0.61) | MCHR1 | |
| SCHEMBL157317 | 0.77 | MCHR1 (1.00) | MCHR1 | |
| Hydrochloric Acid SCHEMBL159744 | 0.76 | MCHR1 (0.98) | MCHR1 | |
| SCHEMBL9968754 | 0.74 | MCHR1 (0.65) | MCHR1GRM2KCNH2 | |
| SCHEMBL9968724 | 0.73 | MCHR1 (0.63) | MCHR1 | |
| SCHEMBL158631 | 0.72 | MCHR1 (0.37) | MCHR1GRM2KCNK3KCNK9 | |
| SCHEMBL157474 | 0.71 | MCHR1 (0.64) | MCHR1 | |
| SCHEMBL158682 | 0.70 | MCHR1 (0.66) | MCHR1 | |
| SCHEMBL9963959 | 0.69 | MCHR1 (0.60) | MCHR1KCNH2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629158-B2 | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20120058939-A9 | AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20110003737-A1 | AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058939-A9 | AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | MCHR1, MCHR2, TAAR1 | MCHR1 1/4885GRM2 333/4885KCNH2 2716/4885 |
| US-20110003737-A1 | AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | MCHR1, MCHR2, TAAR1 | MCHR1 1/4885GRM2 333/4885KCNH2 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.